News & events

Exchanging, meeting
and sharing

 

 

Experience our latest technological development
and innovations by sharing our projects and successes.

We want to share with you each step
of our growth.

Follow us on social networks.
Let’s meet during one of our upcoming congress.

Apr. 02, 2020 - Demo of the new COVID-19 dedicated protocol

This protocol incudes many clinical key points, particularly about screening, analysis of the pathological stages as well as clinical evolutions.
Watch the replay >

Jun. 26, 2019 - PI-RADS, what's new!? - New elements to improve detection, localization, characterization and risk stratification

During this webinar we will discuss the new features of this standard in the image data acquisition, the interpretation criteria and the role of the biparametric MRI.
Watch the replay >

Press releases

June 1st, 2022 - Intrasense signs a strategic partnership with Nurea

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, and Nurea, a leading provider of decision support and diagnostic software for vascular diseases, announce the signing of a partnership that will make Nurea's artificial intelligence solution available to clinicians within the
Myrian platform, through the Intrasense AI Hub. LEARN MORE >

 

May 17, 2022 - Intrasense launches its AI Hub in partnership with Milvue

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, announces, in partnership with the company Milvue, the first integration of a solution within its Hub dedicated to artificial intelligence. The AI Hub enables the simple and ergonomic integration of artificial intelligence algorithms and their orchestration within clinical applications to better meet the
needs of users. LEARN MORE >

 

Apr. 20, 2022 - Availability of the 2021 annual financial report

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, announces today the publication of its Annual Financial Report for the year ended December 31, 2021. This Annual Financial Report was approved by the Board of Directors on April 19, 2022. LEARN MORE >

 

Apr. 5, 2022 - TeleDiag chooses Intrasense by signing a commercial contract for teleradiology 

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, and TeleDiag, a leading player in teleradiology in France entered into a partnership for the deployment of the Myrian® platform to strengthen clinical efficiency and the management of cancer patients. Learn more >

 

Mar.10, 2022 - Intrasense 2021 results: record business growth

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian®, is today publishing audited 2021 consolidated IFRS financial statements for the Group. Learn more >

 

1st Feb, 2022 - Intrasense and Forcomed sign a five-year strategic partnership agreement

Intrasense and Forcomed, a leading provider of continuing medical education, have entered into a five-year partnership to enable radiologists and radiology technicians to use Myrian® during a new training module on breast imagin. Learn more >

 

Jan 24, 2022 - Intrasense: ambitions and publication calendar for 2022

Intrasense hereby sets out its ambitions, development
plan and financial publication timetable for 2022. Learn more >

 

Jan 18, 2022 - Half year report of Intrasense’s liquidity contract signed with
TSAF –Tradition Securities And Futures

Intrasense announces the publication of its half year
liquidity contract signed with TSAF – Tradition Securities And Futures. Learn more >

 

Oct 05, 2021 - New product line in oncology: a milestone passed with the signature of a partnership between Intrasense and I-SERIS

Intrasense and the medical imaging and radiology group I-SERIS, which includes the clinics of Clémentville (Montpellier), Clermont l'Hérault and the scanner center of the Pasteur clinic in Pézenas, announce the signing of an agreement for the development of the new oncology solution Myra. Learn more >

 

Sep 22, 2021 - HY 2021 Consolidated Results Intrasense Group

Intrasense announces its 2021 consolidated IFRS half-year results at Group level as of June 30, 2021. Learn more >

 

Sep 14, 2021 - Intrasense participates in the SIFEM 2021 congress from September 17 to 19

Intrasense is pleased to announce its participation in the congress of the Société d'Imagerie de la Femme, in Ajaccio from September 17 to 19. Learn more >

Sep 07, 2021 - Intrasense provides an update on its development strategy and growth prospects

Intrasense provides an update on its development strategy following its successful capital increase in June 2021. Learn more >

Jun 22, 2021 - Intrasense: successful Rights Issue with €4.9 million raised

Intrasense today announced the success of its capital increase through the issuance of new shares (“New Shares”) with shareholders’ preferential subscription rights, for which subscriptions took place between May 28 and June 15, 2021 (the “Rights Issue”). Learn more >

May 24, 2021 - Intrasense launches a Rights Issue

Intrasense launch a capital increase through the issuance of new shares with shareholders’ preferential subscription rights. Learn more >

Apr. 30, 2021 - Intrasense announces the publication of the annual financial report

Intrasense today announces the publication of its annual financial report for the financial year ended on December 31, 2020. Learn more >

Apr. 08, 2021 - Intrasense announces the referencing of its Myrian® platform with Vidi, first cooperative network of medical imaging groups in France

Intrasense and Vidi, the leading cooperative network of medical imaging groups in France, signed an agreement on January 30th, 2021 to reference Myrian® solutions. Learn more >

Apr. 01, 2021 - New Myrian platform launch, enriched with many new clinical features dedicated to stroke, breast cancer and cardiovascular pathologies

Intrasense is pleased to present the new version 2.9, with a focus on new clinical features. Learn more >

Mar. 23, 2021 - Intrasense Group consolidated 2020 annual results

Intrasense announces its 2020 IFRS Group consolidated annual results. Learn more >

Fev. 11, 2021 - Intrasense and MeVis sign a strategic partnership

Intrasense and MeVis Medical Solutions AG specialized in
the development of clinical applications integrating artificial intelligence, announce a global partnership in the field of lung diseases. Learn more >

Jan. 29, 2021 - Half year report of Intrasense’s liquidity contract signed with TSAF – Tradition Securities And Futures

Intrasense announces the publication of its half year liquidity contract signed with TSAF – Tradition Securities And Futures. Learn more >

Jan. 13, 2021 - New Group Chief Business Officer

Intrasense strengthens its management team with the appointment of Khalil Filali as Group Chief Business Officer. Learn more >

Nov. 12, 2020 - New Group Chief Financial Officer

Intrasense announces the appointment of Lionel Seltz as Group Chief Financial Officer. Financial expertise and international background in structuring growing companies to meet the new corporate development requirements. Learn more >

Nov. 04, 2020 - Myrian 2.8 launch, new clinical applications and workflow efficiency

Intrasense is pleased to present the new version 2.8 of its visualization platform with many new features, from clinical applications to improved workflow. Learn more >

Oct. 08, 2020 - Partial renewal and strengthening of the board of directors

Intrasense announces following a Board meeting on October 8th, 2020, a partial renewal and strengthening of its composition. Michèle Lesieur is coopted as administrator and appointed Chairman of the Board. Anne Larpin is coopted as administrator of the company. The ratification of these cooptations will be submitted to the next ordinary general meeting. Learn more >

Sep. 30, 2020 - HY 2020 Consolidated Results Intrasense Group

Intrasense announces its 2020 consolidated IFRS half-year results at Group level as of June 30, 2020. Learn more >

Apr. 21, 2020 - CE marking for the CT protocol dedicated to COVID-19

Intrasense announces that the scanner reading protocol dedicated to COVID-19 has obtained its CE marking as a world premiere. Learn more >

Apr. 16, 2020 - New version of the COVID-19 protocol

Intrasense continues its involvement in the fight against COVID-19 and announces the availability on Friday April 17th, 2020 of a second version of its scanner reading protocol dedicated to the epidemic. Learn more >

Apr. 02, 2020 - Intrasense and Compagnie de Télémédecine join forces in the fight against COVID-19

Intrasense combines its technological expertise with the clinical expertise of the Compagnie de Télémédecine (CTM Groupe) by deploying to all of the group's radiotherapy specialists the new scanner reading protocol dedicated to COVID-19. Learn more >

Mar. 30, 2020 - Availability of a new COVID-19 dedicated protocol

The company announces the release and immediate availability of a specific scanner reading protocol dedicated to COVID-19. Learn more >

Feb. 10, 2020 - Profitability meeting with 2019 annual results

Intrasense™ announces its 2019 annual results. Learn more >

Dec. 19, 2019 - Intrasense™ announces the end of the BCS financing contract

Intrasense™ announces the end of the BCS (Bond Convertible into Shares) financing contract concluded with the Luxembourgish fund European High Growth Opportunities Securitization Fund (EHGO). Learn more >

Nov. 19, 2019 - Intrasense™ showcases innovative solutions at RSNA 2019

Artificial intelligence will be highlighted on Intrasense™ booth (#6956). The new version of Myrian® platform enabling artificial intelligence to truly be embedded into the daily workflow and clinical routine.Learn more >

Sep. 30, 2019 - Intrasense™ presents its innovations at JFR 2019 show

All innovations will be presented at JFR 2019 on the Intrasense ™ booth (# 213A). The new version of Myrian® as well as the XP-Mammo application will be display.Learn more >

Sep. 24, 2019 - The new version of Myrian® 2.7 unveiled, many clinical innovations

This new version of Myrian® brings many clinical innovations and a new application.Learn more >

Jul. 11, 2019 - 2019 Half -Year Results: strong growth in all financial indicators and convertible bonds contract suspension maintained

Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.Learn more >

Jun. 03, 2019 - Myrian® XP-Mammo has been CE marked

Myrian® XP-Mammo, can now be commercialized on the European market.Learn more >

Apr. 24, 2019 - Braincarta choose Myrian® to industrialize its application

Elonav, a brand-new application dedicated to specifical needs of neurosurgeons.Learn more >

Feb. 05, 2019 - Intrasense 2018 annual results bear first fruits of its new strategy

Strong growth, reaching operating balance.
Learn more >

Jan. 28, 2019 - Suspension of financing contract of bonds convertible into shares issuance

suspension of the automatic drawdowns of bounds convertible into shares (« OCA »), initially planned in the contract signed on August 27, 2018.
Learn more >

Congresses

RSNA 2021

November 28-December 2, 2021
McCormick Place
Chicago - USA

ARAB HEALTH 2022

January 24-27, 2022
DWTC
Dubaï

Talking about Myrian®

Scientific publications

Read scientific papers >

Success stories

Read 4 success stories >

Thank you for your interest in Intrasense.
Do not hesitate to contact us.


Contact

Stay tuned for our latest news and join us
on LinkedIn, Twitter, YouTube and WeChat.

Intrasense_blanc

map_20161028

Headquarters / Siège social :
1231, avenue du Mondial 98
34000 MONTPELLIER | FRANCE